The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors
Open accessAbstract
BACKGROUND: Desmoid tumors are rare, locally aggressive, highly recurrent soft-tissue tumors without approved treatments. METHODS: We conducted a phase 3, international, double-blind, randomized, placebo-controlled trial of nirogacestat in adults with progressing desmoid tumors according to the Response Evaluation Criteria in Solid Tumors, version 1.1. Patients were assigned in a 1:1 ratio to receive the oral γ-secretase inhibitor nirogacestat (150 mg) or placebo twice daily. The primary end point was progression-free survival. RESULTS: From May 2019 through August 2020, a total of 70 patients were assigned to receive nirogacestat and 72 to receive placebo. Nirogacestat had a significant progression-free survival benefit over placebo (hazard ratio for disease progression or death, 0.29; 95% confidence interval, 0.15 to 0.55; P<0.001); the likelihood of being event-free at 2 years was 76% with nirogacestat and 44% with placebo. Between-group differences in progression-free survival were consistent across prespecified subgroups. The percentage of patients who had an objective response was significantly higher with nirogacestat than with placebo (41% vs. 8%; P<0.001), with a median time to response of 5.6 months and 11.1 months, respectively; the percentage of patients with a complete response was 7% and 0%, respectively. Significant between-group differences in secondary patient-reported outcomes, including pain, symptom burden, physical or role functioning, and health-related quality of life, were observed (P≤0.01). Frequent adverse events with nirogacestat included diarrhea (in 84% of the patients), nausea (in 54%), fatigue (in 51%), hypophosphatemia (in 42%), and maculopapular rash (in 32%); 95% of adverse events were of grade 1 or 2. Among women of childbearing potential receiving nirogacestat, 27 of 36 (75%) had adverse events consistent with ovarian dysfunction, which resolved in 20 women (74%). CONCLUSIONS: Nirogacestat was associated with significant benefits with respect to progression-free survival, objective response, pain, symptom burden, physical functioning, role functioning, and health-related quality of life in adults with progressing desmoid tumors. Adverse events with nirogacestat were frequent but mostly low grade. (Funded by SpringWorks Therapeutics; DeFi ClinicalTrials.gov number, NCT03785964.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Notch Signaling in Development, Tissue Homeostasis, and Disease
Siebel, C., & Lendahl, U. (2017) · Physiological Reviews · doi:10.1152/physrev.00005.2017 · Cited by 978
Alman, B., Attia, S., Baumgarten, C., Benson, C., Blay, J.-Y., Bonvalot, S., Breuing, J., Cardona, K., Casali, P. G., van Coevorden, F., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2019.11.013 · Cited by 506
Self-citationVasomotor Symptoms and Menopause: Findings from the Study of Women's Health across the Nation
Thurston, R. C., & Joffe, H. (2011) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2011.05.006 · Cited by 466
Sorafenib for Advanced and Refractory Desmoid Tumors
Gounder, M. M., Mahoney, M. R., Van Tine, B. A., Ravi, V., Attia, S., Deshpande, H. A., Gupta, A. A., Milhem, M. M., Conry, R. M., Movva, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805052 · Cited by 463
Self-citationKasper, B., Baumgarten, C., Garcia, J., Bonvalot, S., Haas, R., Haller, F., Hohenberger, P., Penel, N., Messiou, C., van der Graaf, W. T., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx323 · Cited by 422
Self-citationTargeting Notch signaling pathway in cancer: Clinical development advances and challenges
Takebe, N., Nguyen, D., & Yang, S. X. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.09.005 · Cited by 413
Salas, S., Dufresne, A., Bui, B., Blay, J.-Y., Terrier, P., Ranchere-Vince, D., Bonvalot, S., Stoeckle, E., Guillou, L., Le Cesne, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5489 · Cited by 382
Coric, V., van Dyck, C. H., Salloway, S., Andreasen, N., Brody, M., Richter, R. W., Soininen, H., Thein, S., Shiovitz, T., Pilcher, G., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.2194 · Cited by 374
Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors
Schott, A. F., Landis, M. D., Dontu, G., Griffith, K. A., Layman, R. M., Krop, I., Paskett, L. A., Wong, H., Dobrolecki, L. E., Lewis, M. T., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3326 · Cited by 277
γ-Secretase inhibitors and modulators
Golde, T. E., Koo, E. H., Felsenstein, K. M., Osborne, B. A., & Miele, L. (2013) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2013.06.005 · Cited by 272
Penel, N., Le Cesne, A., Bui, B. N., Perol, D., Brain, E. G., Ray-Coquard, I., Guillemet, C., Chevreau, C., Cupissol, D., Chabaud, S., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq341 · Cited by 235
Messersmith, W. A., Shapiro, G. I., Cleary, J. M., Jimeno, A., Dasari, A., Huang, B., Shaik, M. N., Cesari, R., Zheng, X., Reynolds, J. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0607 · Cited by 218
Toulmonde, M., Pulido, M., Ray-Coquard, I., Andre, T., Isambert, N., Chevreau, C., Penel, N., Bompas, E., Saada, E., Bertucci, F., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30276-1 · Cited by 206
Wei, P., Walls, M., Qiu, M., Ding, R., Denlinger, R. H., Wong, A., Tsaparikos, K., Jani, J. P., Hosea, N., Sands, M., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0034 · Cited by 195
Kummar, S., O'Sullivan Coyne, G., Do, K. T., Turkbey, B., Meltzer, P. S., Polley, E., Choyke, P. L., Meehan, R., Vilimas, R., Horneffer, Y., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.1994 · Cited by 183
Self-citationA critical analysis of treatment strategies in desmoid tumours: a review of a series of 106 cases
Stoeckle, E., Coindre, J. M., Longy, M., Binh, M. B. N., Kantor, G., Kind, M., de Lara, C. T., Avril, A., Bonichon, F., & Bui, B. N. (2008) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2008.06.1495 · Cited by 133
Safety profile of semagacestat, a gamma-secretase inhibitor: IDENTITY trial findings
Henley, D. B., Sundell, K. L., Sethuraman, G., Dowsett, S. A., & May, P. C. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.939167 · Cited by 109
The role of Notch signaling in the mammalian ovary
Vanorny, D. A., & Mayo, K. E. (2017) · Reproduction · doi:10.1530/rep-16-0689 · Cited by 103
Targeting the N otch pathway: A potential therapeutic approach for desmoid tumors
Shang, H. F., Braggio, D., Lee, Y., Sannaa, G. A. A., Creighton, C. J., Bolshakov, S. V., Lazar, A. J., Lev, D. C., & Pollock, R. E. (2015) · Cancer · doi:10.1002/cncr.29564 · Cited by 85
Evolving strategies for management of desmoid tumor
Riedel, R. F., & Agulnik, M. (2022) · Cancer · doi:10.1002/cncr.34332 · Cited by 84
Self-citationSahebjam, S., Bedard, P. L., Castonguay, V., Chen, Z., Reedijk, M., Liu, G., Cohen, B. L., Zhang, W.-J., Clarke, B. A., Zhang, T., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.380 · Cited by 75
Mesenchymal Stromal Cell Mutations and Wound Healing Contribute to the Etiology of Desmoid Tumors
Carothers, A. M., Rizvi, H. A., Hasson, R. M., Heit, Y. I., Davids, J. S., Bertagnolli, M. M., & Cho, N. L. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-2819 · Cited by 67
Villalobos, V. M., Hall, F., Jimeno, A., Gore, L., Kern, K. A., Cesari, R., Huang, B., Schowinsky, J. T., Blatchford, P. J., Hoffner, B., et al. (2017) · Annals of Surgical Oncology · doi:10.1245/s10434-017-6082-1 · Cited by 59
Molecular pathogenesis of desmoid tumor and the role of γ-secretase inhibition
Federman, N. C. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00308-1 · Cited by 57
Self-citationGounder, M. M., Maddux, L., Paty, J. A., & Atkinson, T. M. (2019) · Cancer · doi:10.1002/cncr.32555 · Cited by 56
Self-citationDesmoid fibromatosis through the patients’ eyes: time to change the focus and organisation of care?
Husson, O., Younger, E., Dunlop, A., Dean, L., Strauß, D., Benson, C., Hayes, A. J., Miah, A. B., van Houdt, W. J., Zaidi, S., et al. (2018) · Supportive Care in Cancer · doi:10.1007/s00520-018-4386-8 · Cited by 50
Self-citationThe epidemiology of desmoid tumors in Denmark
Anneberg, M., Svane, H. M. L., Fryzek, J. P., Nicholson, G., White, J. B., Edris, B., Smith, L. M., Hooda, N., Petersen, M. M., Baad‐Hansen, T., et al. (2022) · Cancer Epidemiology · doi:10.1016/j.canep.2022.102114 · Cited by 30
Self-citationGronchi, A., & Raut, C. P. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2636-4 · Cited by 20
Cited by
Notch signaling pathway in cancer: from mechanistic insights to targeted therapies
Shi, Q., Xue, C., Zeng, Y., Yuan, X., Chu, Q., Jiang, S., Wang, J., Zhang, Y., Zhu, D., & Li, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01828-x · Cited by 401
De Strooper, B., & Karran, E. (2024) · The EMBO Journal · doi:10.1038/s44318-024-00057-w · Cited by 36
Metadata
- Authors
- Gounder, M., Ratan, R., Alcindor, T., Schöffski, P., van der Graaf, W. T., Wilky, B. A., Riedel, R. F., Lim, A., Smith, L. M., Moody, S., Attia, S., Chawla, S., D’Amato, G., Federman, N., Merriam, P., Van Tine, B. A., Vincenzi, B., Benson, C., Bui, N. Q., Chugh, R., Tinoco, G., Charlson, J., Dileo, P., Hartner, L., Lapeire, L., Mazzeo, F., Palmerini, E., Reichardt, P., Stacchiotti, S., Bailey, H. H., Burgess, M. A., Cote, G. M., Davis, L. E., Deshpande, H., Gelderblom, H., Grignani, G., Loggers, E., Philip, T., Pressey, J. G., Kummar, S., & Kasper, B.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-03-09
- Volume
- 388
- Issue
- 10
- Pages
- 898-912
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4323532421
- Cited by
- 273
- References
- 28
- FWCI
- 47.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.